Takeda Pharmaceutical (NYSE:TAK) Insider Nicola Deidre Petal Greenway Sells 6,774 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Nicola Deidre Petal Greenway sold 6,774 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $115,835.40. Following the completion of the transaction, the insider directly owned 53,029 shares in the company, valued at $906,795.90. This trade represents a 11.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $17.42 on Thursday. The firm has a market cap of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. The firm has a fifty day moving average price of $16.49 and a 200 day moving average price of $17.13. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, sell-side analysts expect that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Key Stories Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Insiders continued to hold substantial positions after the transactions, suggesting the sales do not necessarily reflect a loss of confidence in Takeda’s business or outlook. The filings state that the shares were sold to cover tax withholding obligations related to vested equity awards. SEC insider filing
• Neutral Sentiment: Analyst sentiment remains mixed: ratings include two Buys, one Hold and one Sell, resulting in an overall “Hold” consensus. Recent institutional buying has also provided some support, but those purchases were relatively small compared with Takeda’s market capitalization. Takeda stock analysis
• Negative Sentiment: Multiple senior executives and insiders sold a combined 399,? shares at an average price of $17.10. CEO Julie So-Young Kim sold 89,090 shares, Andrew Stewart Plump sold 165,393 shares and General Counsel Natalie Anne Marie Furney sold 30,868 shares. Other insiders also reduced their holdings by approximately 5.9% to 17.8%, which could weigh on investor sentiment despite the tax-related explanation. Takeda insider sales report

Hedge Funds Weigh In On Takeda Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after purchasing an additional 2,854,069 shares during the period. UBS Group AG increased its position in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares during the last quarter. Qube Research & Technologies Ltd raised its holdings in Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after buying an additional 1,426,184 shares during the period. Van ECK Associates Corp lifted its position in Takeda Pharmaceutical by 98.4% in the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after buying an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its stake in Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after buying an additional 880,289 shares during the period. 9.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Takeda Pharmaceutical presently has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.